BCL2 and Miyoshi myopathy: An exception is the selective activity of the BCL2 inhibitor venetoclax in t(11;14) MM (Kumar et al.2020) for reasons not completely understood but attributed to t(11;14) MM having a more lymphoplasmacytic, B cell–like phenotype (Fonseca et al. 2002).